Abstract / Summary
To evaluate the efficacy and safety of cadonilimab in patients with solid tumors. We systematically searched seven databases-PubMed, Embase, Web of Science, Cochrane Library, Ovid MEDLINE, Scopus, and ProQuest-for clinical studies published up to July 19, 2025. Inclusion criteria encompassed randomized controlled trials (RCTs) and single-arm trials. Data collected included objective response rate (ORR), disease control rate (DCR), overall survival (OS), progression-free survival (PFS), and adverse events (AEs) incidence. A meta-analysis of relevant data was performed using a random-effects model. This study encompassed a total of 13 investigations, comprising 11 single-arm clinical trials, and 2 randomized controlled trials. A total of 1,359 patients with solid tumors, including gastric cancer or adenocarcinoma of the gastroesophageal junction and cervical non-small cell lung cancer, were enrolled in the study. The pooled efficacy analysis demonstrated an ORR of 0.45 (95% CI: 0.31-0.59), a DCR of 0.84 (95% CI: 0.71-0.94), a median PFS of 7.47 months (95% CI: 4.98-9.97), and a median OS of 12.89 months (95% CI: 10.09-15.68). Subgroup analysis indicated the highest ORR in cervical cancer (0.63, 95% CI: 0.33-0.94), while the highest DCR was observed in gastric or gastroesophageal junction adenocarcinoma (0.91, 95% CI: 0.82-1.00). The administration of cadonilimab at a dosage of 10 mg/kg every three weeks resulted in the optimal ORR and DCR of 0.71 (95% CI: 0.63-0.80) and 0.95 (95% CI: 0.90-0.99), respectively. A comparison of cadonilimab plus chemotherapy with monotherapy or combination therapy with targeted agents revealed that the former demonstrated superior efficacy, with an ORR and DCR of 0.62 (95% CI: 0.56-0.69) and 0.94 (95% CI: 0.88-1.00), respectively. With respect to safety, the incidence rate of adverse events of any grade was 0.99 (95% CI: 0.98-1.00), the incidence of ≥Grade 3 treatment-related adverse events (TRAEs) was 0.49 (95% CI: 0.34-0.63), and the incidence of ≥Grade 3 immune-related adverse events (irAEs) was 0.11 (95% CI: 0.08-0.14). The most prevalent TRAEs included neutrophil count decreased, anemia, and platelet count decreased. Cadonilimab demonstrates a positive response in the treatment of various solid tumors, exhibiting good tolerability. https://www.crd.york.ac.uk/prospero/, identifier CRD420251103576.
Primary Source
Frontiers in immunology
Ask Prognia AI
Have questions about this meta-analysis?
Prognia AI can search this source alongside 35M+ PubMed papers and current ESC, AHA, NICE, and ADA guidelines to give you a fully cited clinical answer.